These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 3491897)

  • 1. Pharmacokinetics of intravenous bepridil in patients with coronary disease.
    Lesko LJ; Benotti JR; Alpert JS; Brady PM; McCue JE; Weiner BH; Ockene IS
    J Pharm Sci; 1986 Oct; 75(10):952-4. PubMed ID: 3491897
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and metabolism of bepridil.
    Benet LZ
    Am J Cardiol; 1985 Mar; 55(7):8C-13C. PubMed ID: 3872057
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Hemodynamic effects of a new calcium antagonist, bepridil, in patients with coronary artery disease].
    Haerer VW; Stauch M
    Arzneimittelforschung; 1987 Jul; 37(7):829-31. PubMed ID: 3499908
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular actions after intravenous and intracoronary administration of the slow channel blocker bepridil.
    Verdouw PD; Scheffer MG
    Arzneimittelforschung; 1984; 34(1):21-5. PubMed ID: 6608356
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute hemodynamic and antiischemic properties of intravenous bepridil in coronary artery disease.
    Remme WJ; Kruyssen DA; Van Hoogenhuyze DC; Hofman B; Krauss XH; Storm CJ
    Am J Cardiol; 1989 Mar; 63(11):670-5. PubMed ID: 2784281
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical pharmacology of calcium inhibitors].
    Singlas E; Martre H; Taburet AM
    Arch Mal Coeur Vaiss; 1985 Nov; 78 Spec No():15-22. PubMed ID: 3937500
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hemodynamic assessment of intravenous bepridil administration in ischemic heart disease.
    Tamari I; Borer JS; Moses JW; Goldberg HL; Fisher J; Wallis JB; Halle A
    Am J Cardiol; 1985 Mar; 55(7):25C-29C. PubMed ID: 3872054
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hemodynamic effects of intravenous bepridil in patients with normal left ventricular function.
    Alpert JS; Benotti JR; Brady PM; McCue JE; Weiner BH; Ockene IS
    Am J Cardiol; 1985 Mar; 55(7):20C-24C. PubMed ID: 3872053
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects on hemodynamics and left ventricular ejection fraction of intravenous bepridil for impaired left ventricular function secondary to coronary artery disease.
    Josephson MA; Mody T; Coyle K; Singh BN
    Am J Cardiol; 1987 Jul; 60(1):44-9. PubMed ID: 3496779
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bepridil for chronic stable angina pectoris: results of a prospective multicenter, placebo-controlled, dose-ranging study in 77 patients.
    DiBianco R; Alpert J; Katz RJ; Spann J; Chesler E; Ferri DP; Larca LJ; Costello RB; Gore JM; Eisenman MJ
    Am J Cardiol; 1984 Jan; 53(1):35-41. PubMed ID: 6362386
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dose related coronary and systemic haemodynamic effects of intravenous bepridil in patients with coronary artery disease.
    Remme WJ; van Hoogenhuyze DC; Krauss XH; Hofman A; Storm CJ; Kruyssen HA
    Eur Heart J; 1987 Feb; 8(2):130-40. PubMed ID: 3494607
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Hemodynamic and coronary changes induced by various slow-channel inhibitors in chronic coronary insufficiency: nifedipine, verapamil and bepridil].
    Merillon JP; Duffloux MA; Eustigneff T; Pansard Y; Guiomard A; Zygelman M; Aumont MC; Gourgon R
    Therapie; 1981; 36(2):123-34. PubMed ID: 6270840
    [No Abstract]   [Full Text] [Related]  

  • 13. The binding of the calcium channel blocker, bepridil, to calmodulin.
    Itoh H; Tanaka T; Mitani Y; Hidaka H
    Biochem Pharmacol; 1986 Jan; 35(2):217-20. PubMed ID: 3484629
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Anti-angina effect of the calcium antagonist bepridil in stable angina pectoris].
    Schneider W; Mehlhorn C; Kaltenbach M; Bussmann WD
    Z Kardiol; 1985 Jun; 74(6):341-7. PubMed ID: 3895761
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of buflomedil after intravenous administration in patients with chronic renal failure.
    Rey E; d'Athis P; Richard MO; Fillastre JP; Olive G
    Int J Clin Pharmacol Ther Toxicol; 1984 Dec; 22(12):648-52. PubMed ID: 6526539
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of bepridil on the electrophysiologic properties of isolated canine and rabbit myocardial fibers.
    Kato R; Singh BN
    Am Heart J; 1986 Feb; 111(2):271-9. PubMed ID: 3484892
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Electrophysiological profile of bepridil, a new anti-anginal drug with calcium blocking properties.
    Flammang D; Waynberger M; Jansen FH; Paillet R; Coumel P
    Eur Heart J; 1983 Sep; 4(9):657-54. PubMed ID: 6605854
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nifedipine, diltiazem, bepridil and verapamil uptakes into cardiac and smooth muscles.
    Pang DC; Sperelakis N
    Eur J Pharmacol; 1983 Feb; 87(2-3):199-207. PubMed ID: 6601581
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The relationship between the binding site of [3H]-d-cis-diltiazem and that of other non-dihydropyridine calcium entry blockers in cardiac sarcolemma.
    Balwierczak JL; Johnson CL; Schwartz A
    Mol Pharmacol; 1987 Feb; 31(2):175-9. PubMed ID: 2433570
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of bepridil on exercise tolerance in chronic stable angina: a double-blind, randomized, placebo-controlled, crossover trial.
    Hill JA; O'Brien JT; Scott E; Conti CR; Pepine CJ
    Am J Cardiol; 1984 Mar; 53(6):679-83. PubMed ID: 6367414
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.